Diagnosis and Treatment Patterns in Celiac Disease

Cichewicz, Allie; Mearns, Elizabeth S.; Taylor, Aliki; Boulanger, Talia; Gerber, Michele; Leffler, Daniel A.; Drahos, Jennifer; Sanders, David S.; Craig, Kelly Jean Thomas; Lebwohl, Benjamin

doi:10.1007/s10620-019-05528-3

Cited by 54 publications

(52 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serological tests are the first line investigation for the screening of patients suspected to have CeD. Until the late 1950s, there was no biomarker for the diagnosis of CeD, and the diagnosis made was on the basis of the presence of suggestive clinical symptoms and resolution of symptoms with a GFD [7]. The advent of methods for obtaining intestinal biopsies such as Crosby capsules and endoscopic techniques, added villous atrophy as one of the most specific requirements for the diagnosis of CeD.…”

Section: Serological Biomarkersmentioning

confidence: 99%

Non-Invasive Biomarkers for Celiac Disease

Singh

Pramanik

Acharya

et al. 2019

JCM

View full text Add to dashboard Cite

Once thought to be uncommon, celiac disease has now become a common disease globally. While avoidance of the gluten-containing diet is the only effective treatment so far, many new targets are being explored for the development of new drugs for its treatment. The endpoints of therapy include not only reversal of symptoms, normalization of immunological abnormalities and healing of mucosa, but also maintenance of remission of the disease by strict adherence of the gluten-free diet (GFD). There is no single gold standard test for the diagnosis of celiac disease and the diagnosis is based on the presence of a combination of characteristics including the presence of a celiac-specific antibody (anti-tissue transglutaminase antibody, anti-endomysial antibody or anti-deamidated gliadin peptide antibody) and demonstration of villous abnormalities. While the demonstration of enteropathy is an important criterion for a definite diagnosis of celiac disease, it requires endoscopic examination which is perceived as an invasive procedure. The capability of prediction of enteropathy by the presence of the high titer of anti-tissue transglutaminase antibody led to an option of making a diagnosis even without obtaining mucosal biopsies. While present day diagnostic tests are great, they, however, have certain limitations. Therefore, there is a need for biomarkers for screening of patients, prediction of enteropathy, and monitoring of patients for adherence of the gluten-free diet. Efforts are now being made to explore various biomarkers which reflect different changes that occur in the intestinal mucosa using modern day tools including transcriptomics, proteomics, and metabolomics. In the present review, we have discussed comprehensively the pros and cons of available biomarkers and also summarized the current status of emerging biomarkers for the screening, diagnosis, and monitoring of celiac disease.

show abstract

Section: Serological Biomarkersmentioning

confidence: 99%

Non-Invasive Biomarkers for Celiac Disease

Singh

Pramanik

Acharya

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Gerade die nicht klassischen und extraintestinalen Symptome der Zöliakie nehmen anscheinend in den letzten Jahren zu [16]. In der westlichen Welt sehen wir bei Erstdiagnose nur noch selten das klassische Bild der Zöliakie.…”

Section: Gestalt Der Zöliakie In Der Heutigen Zeitunclassified

Zöliakie und Weizensensitivität im Wandel – ein Update

Hübener¹,

Manthey²

2019

Gastroenterologie up2date

View full text Add to dashboard Cite

“…The clinical presentation of CD has changed over time, with "nonclassical CD" (extraintestinal symptoms) being more common than classical symptoms of malabsorption [13]. Out of the atypical manifestations of CD, liver involvement is among the most common [14].…”

Section: Introductionmentioning

confidence: 99%

Celiac Disease, Gluten-Free Diet, and Metabolic and Liver Disorders

et al. 2020

View full text Add to dashboard Cite

Celiac disease (CD) is a chronic autoimmune enteropathy triggered by the ingestion of gluten in genetically predisposed individuals. At the time of diagnosis, the frequency of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis in individuals with CD appears to be similar to that of the general population, although a lower body mass index and a lower rate of hypercholesterolemia and type 2 diabetes mellitus are observed at diagnosis in CD patients. The effect of a gluten-free diet (GFD) in individuals with these liver and metabolic disorders is still a matter of debate. The aim of this study was to investigate the links between a GFD and metabolic/liver disorders in CD patients. A systematic electronic search of the literature from January 2009 to December 2019 was performed using Medline, Web of Science, Scopus, and the Cochrane Library. Only papers written in English concerning metabolic and liver disorders in adult patients with CD were included. Out of 1195 citations, 14 eligible studies were identified. Increases in the frequency of NAFLD, weight gain, and alterations of the lipid profile suggest that important changes happen in celiac patients on a GFD, though the physiopathology of these conditions is unclear. Although a GFD is the only effective treatment available for CD, liver function, body weight, and metabolic and nutritional profiles should be monitored in patients on a GFD.

show abstract

Diagnosis and Treatment Patterns in Celiac Disease

Cited by 54 publications

References 111 publications

Non-Invasive Biomarkers for Celiac Disease

Non-Invasive Biomarkers for Celiac Disease

Zöliakie und Weizensensitivität im Wandel – ein Update

Celiac Disease, Gluten-Free Diet, and Metabolic and Liver Disorders

Contact Info

Product

Resources

About